3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Melanoma
3
Lymphoma, T-Cell, Cutaneous
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
16
Cyclophosphamide
8
Nivolumab
7
Gemcitabine
6
Paclitaxel
5
Drug Therapy
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Oxaliplatin
4
Fluorouracil
4
Carboplatin
4
ulixertinib
3
spartalizumab
3
Trastuzumab
3
Radiotherapy
3
Leucovorin
3
Capecitabine
3
trametinib
2
tovorafenib
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
palbociclib
2
osimertinib
2
enzalutamide
2
cemiplimab
2
atezolizumab
2
Taxes
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Interleukin-15
×
Dermatologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled